Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PhylloZyme is a private biotechnology company developing plant-derived enzyme and botanical input technologies, with a current commercial focus on sustainable agriculture. The company describes its proprietary BST (Botanical Sap Technology) platform as a way to convert post-harvest plant residues into enzyme-rich agricultural products intended to improve soil health, plant growth, and crop yields. Historical company materials also describe an earlier platform centered on producing shelf-stable enzymes in leaves for industrial applications such as food processing, textiles, bioenergy, and animal feed. Based on public information, PhylloZyme appears to operate more as an ag-biotech and industrial enzyme platform company than a human therapeutics developer. It is not primarily a pharma or healthcare company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PhylloZyme.